Pharmanutra S.p.A. (FRA:761)

Market Cap	675.05M +48.6%
Revenue (ttm)	143.70M +17.9%
Net Income	20.74M +22.8%
EPS	2.17 +22.9%
Shares Out	n/a
PE Ratio	32.42
Forward PE	25.08
Dividend	1.20 (1.71%)
Ex-Dividend Date	May 4, 2026

Volume	n/a
Open	70.20
Previous Close	70.80
Day's Range	70.20 - 70.20
52-Week Range	43.75 - 94.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 10, 2026

About Pharmanutra

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for mu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 144
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 761

Financial Performance

In 2025, Pharmanutra's revenue was 132.16 million, an increase of 13.78% compared to the previous year's 116.15 million. Earnings were 20.00 million, an increase of 20.44%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 26, 2026

Data Sources Report a data error